{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:46Z","timestamp":1790286946500,"version":"4.1.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Avelumab, is an anti-PD-L1 immune checkpoint inhibitor (ICI). Like other ICI, avelumab can cause immune-related adverse events. Although rare, sarcoidosis-like granulomatous reactions have been described in patients on anti-CTLA-4 and anti-PD-1 immunotherapy. Here we report a case of treatment emergent cutaneous sarcoidosis in a patient who received avelumab for metastatic colon cancer. A 56-year-old African American woman with metastatic colon cancer that had progressed after multiple lines of treatment, including other immunotherapy agents, was enrolled on a clinical trial with avelumab. While on treatment, the patient developed two skin lesions, and histopathological examination of both biopsies demonstrated chronic granulomatous inflammation in the dermis with multinucleated giant cells containing asteroid bodies, consistent with cutaneous sarcoidosis. Multiplex immunofluorescence revealed parallels between the immune architecture of the patient\u2019s cutaneous sarcoidal lesion and an excised tumor metastasis. Recognizing cutaneous sarcoidosis as a rare adverse effect of ICI immunotherapy is important because sarcoidal lesions can be mistaken for metastatic disease on clinical exam and medical imaging. We noticed similar immune composition of the sarcoidal granuloma and tumor microenvironment. However, further studies are needed to fully elucidate the mechanism of ICI associated sarcoidosis.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1432927","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T07:04:41Z","timestamp":1740985481000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: The immune architecture of immunotherapy-induced cutaneous sarcoidosis resembles peritumoral inflammation"],"prefix":"10.3389","volume":"16","author":[{"given":"Catherine J.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Strong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Gatti-Mays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiem","family":"Lassoued","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Sater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Redman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Brownell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol (Toronto Ont.)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Sci (New York N.Y.)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29040234","article-title":"Cutaneous adverse events associated with immune checkpoint inhibitors: A review article","volume":"29","author":"Chen","year":"2022","journal-title":"Curr Oncol (Toronto Ont.)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30070498","article-title":"Molecular mechanisms of cutaneous immune-related adverse events (irAEs) induced by immune checkpoint inhibitors","volume":"30","author":"Teng","year":"2023","journal-title":"Curr Oncol (Toronto Ont.)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2019.0119","article-title":"Checkpoint inhibitors","volume":"116","author":"Heinzerling","year":"2019","journal-title":"Dtsch Arztebl Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.e14534","article-title":"Toxicities in immunotherapy: Can they predict response","volume":"34","author":"Prior","year":"2016","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1183\/09031936.00107912","article-title":"Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy","volume":"41","author":"Tissot","year":"2013","journal-title":"Eur Respir J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000181","article-title":"Sarcoidosis following anti-PD-1 and anti-CTLA-4 therapy for metastatic melanoma","volume":"40","author":"Reddy","year":"2017","journal-title":"J immunotherapy (Hagerstown Md.: 1997)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2017.11.021","article-title":"Granulomatous reaction in a patient with metastatic melanoma treated with ipilimumab: first case reported with isolated cutaneous findings","volume":"110","author":"Cervantes","year":"2019","journal-title":"Actas dermo-sifiliograficas"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000362614","article-title":"New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment","volume":"37","author":"Murphy","year":"2014","journal-title":"Oncol Res Treat"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000437","article-title":"Sarcoid-like reactions in patients receiving modern melanoma treatment","volume":"28","author":"Dimitriou","year":"2018","journal-title":"Melanoma Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0715","article-title":"Sarcoid-like granulomatosis of the lung related to immune-checkpoint inhibitors: distinct clinical and imaging features of a unique immune-related adverse event","volume":"6","author":"Nishino","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.05.041","article-title":"Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation","volume":"158","author":"Chanson","year":"2021","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201611-863LE","article-title":"Sarcoidosis-like granulomatous lung reaction associated with anti-programmed death receptor-1 ligand therapy","volume":"14","author":"Balestra","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0035","article-title":"Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma","volume":"10","author":"Mitchell","year":"2018","journal-title":"Immunotherapy"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.13386","article-title":"Sarcoidosis-like reaction in metastatic triple negative breast cancer treated by anti-PD-L1","volume":"25","author":"Lafon","year":"2019","journal-title":"Breast J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2709062","DOI":"10.1155\/2022\/2709062","article-title":"Atezolizumab-Induced sarcoidosis-Like reaction in a patient with metastatic breast cancer","volume":"2022","author":"Tsunoda","year":"2022","journal-title":"Case Rep oncological Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1056\/NEJMra071714","article-title":"Sarcoidosis","volume":"357","author":"Iannuzzi","year":"2007","journal-title":"New Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2020.02.024","article-title":"Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis","volume":"131","author":"Chorti","year":"2020","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.06.09","article-title":"18F-fluorodeoxyglucose positron emission tomography\/computed tomography in the diagnosis of benign pulmonary lesions in sarcoidosis","volume":"8","author":"Zhao","year":"2019","journal-title":"Trans Lung Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","article-title":"Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients","volume":"6","author":"Tetzlaff","year":"2018","journal-title":"J immunotherapy Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.051","article-title":"Immune checkpoint inhibitors and the development of granulomatous reactions","volume":"81","author":"Cornejo","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/1203475418776934","article-title":"Erythema nodosum as the initial presentation of nivolumab-induced sarcoidosis-like reaction","volume":"22","author":"Laroche","year":"2018","journal-title":"J cutaneous Med Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201503-0635LE","article-title":"Decreased cytotoxic T-lymphocyte antigen 4 expression on regulatory T cells and th17 cells in sarcoidosis: double trouble","volume":"192","author":"Broos","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201401-0188OC","article-title":"Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity","volume":"190","author":"Braun","year":"2014","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1432927\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T09:00:17Z","timestamp":1741078817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1432927\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2025.1432927"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1432927","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"article-number":"1432927"}}